Edwards Lifesciences (WBO:EWLS) Total Long-Term Assets: €6,135 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:EWLS Edwards Lifesciences Corp WBO:EWLS
94 GF Score
Price €80.80
GF Value €82.44
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Edwards Lifesciences Total Long-Term Assets?

Edwards Lifesciences WBO:EWLS +1.38% 94 Total Long-Term Assets is €6,135 Mil as of Mar. 2026. GuruFocus rates WBO:EWLS with a GF Score™ of 94/100 and a GF Value™ of €82.44 (Fairly Valued). The stock has 5 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Edwards Lifesciences's Total Long-Term Assets for the quarter that ended in Mar. 2026 was €6,135 Mil.

Edwards Lifesciences Total Long-Term Assets Related Terms

Edwards Lifesciences Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Edwards Lifesciences's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edwards Lifesciences Total Long-Term Assets Chart

Edwards Lifesciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,709.88 4,905.69 4,885.32 6,465.26 5,942.39

Edwards Lifesciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,298.88 5,992.27 5,890.13 5,942.39 6,135.01
WBO:EWLS
94GF Score
Edwards Lifesciences Corp WBO:EWLS
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edwards Lifesciences Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of €6,135 Mil mean?
Edwards Lifesciences (WBO:EWLS) has a Total Long-Term Assets of €6,135 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Edwards Lifesciences and its competitors.
Is Edwards Lifesciences' Total Long-Term Assets too high?
Edwards Lifesciences' current Total Long-Term Assets is €6,135 Mil. Overall, Edwards Lifesciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' Total Long-Term Assets compare to BSX and GEHC?
Edwards Lifesciences' Total Long-Term Assets of €6,135 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Medical Devices & Instruments company?
A good Total Long-Term Assets depends on the Medical Devices & Instruments industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Edwards Lifesciences and its competitors. Edwards Lifesciences's current Total Long-Term Assets is €6,135 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Edwards Lifesciences (WBO:EWLS) is currently considered Fairly Valued. The stock's GF Value™ is €82.44, compared to a current price of €80.80 — trading 2% below its estimated fair value. The current Total Long-Term Assets is €6,135 Mil. Edwards Lifesciences' overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Edwards Lifesciences (WBO:EWLS), the current Total Long-Term Assets is €6,135 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Edwards Lifesciences (WBO:EWLS) Overvalued in 2026?

Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued. The current stock price of €80.80 is trading 2% below its estimated GF Value™ of €82.44. GuruFocus considers Edwards Lifesciences to be Fairly Valued.

Key valuation signals for WBO:EWLS:

  • Total Long-Term Assets: €6,135 Mil
  • GF Value™: €82.44 vs. price of €80.80 (2% below fair value)
  • GF Score™: 94/100 with 5 warning signs

No single metric tells the full story. See the WBO:EWLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Edwards Lifesciences Business Description

Address One Edwards Way, Irvine, CA, USA, 92614
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
94GF Score

Get the complete analysis for WBO:EWLS

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€80.80
Price
€82.44
GF Value